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After hepatic microwave ablation, the differentiation between fully necrotic and persistent vital tissue 
through contrast enhanced ct remains a clinical challenge. therefore, there is a need to evaluate new 
imaging modalities, such as ct perfusion (ctp) to improve the visualization of coagulation necrosis. 
MWA and CTP were prospectively performed in five healthy pigs. After the procedure, the pigs were 
euthanized, and the livers explanted. orthogonal histological slices of the ablations were stained with 
a vital stain, digitalized and the necrotic core was segmented. ctp maps were calculated using a dual-
input deconvolution algorithm. the segmented necrotic zones were overlaid on the DicoM images to 
calculate the accuracy of depiction by cect/ctp compared to the histological reference standard. A 
receiver operating characteristic analysis was performed to determine the agreement/true positive rate 
and disagreement/false discovery rate between cect/ctp and histology. Standard cect showed a true 
positive rate of 81% and a false discovery rate of 52% for display of the coagulation necrosis. Using CTP, 
delineation of the coagulation necrosis could be improved significantly through the display of hepatic 
blood volume and hepatic arterial blood flow (p < 0.001). The ratios of true positive rate/false discovery 
rate were 89%/25% and 90%/50% respectively. Other parameter maps showed an inferior performance 
compared to cect.
Microwave ablation (MWA) is a thermoablative method for minimally invasive tumor treatment1. During 
the procedure, high temperatures are generated around the tip of an antenna positioned in the target tissue, 
causing a locally limited coagulation necrosis of the tissue1,2. MWA can be performed under CT guidance for 
exact positioning of the antenna in the target tissue with immediate post-ablation contrast-enhanced computed 
tomography (CECT) to ensure a sufficient ablation of the target tissue. Although CECT has proven to be able to 
visualize ablation margins after thermoablation in studies3–5, a risk of local recurrence remains, even if a tumor 
appears to be fully ablated. This is due to the fact that only the inner parts of the ablated target area become 
fully necrotic, while vital tissue may persist in the outer zone, as shown by pathologic and histologic analyses6–9. 
Contrast-enhanced CT alone cannot accurately display the margins of the coagulation necrosis within an abla-
tion9–11. An imaging technique allowing for an exact visualization of the coagulation necrosis and early detection 
of incomplete tumor coverage could ensure and allow prompt re-ablation and thus possibly lower the rate of 
tumor recurrence.
Previous research suggests, that CT-perfusion (CTP) might improve visualization of ablated areas after ther-
moablation12,13, but, so far, no sufficient analysis has been performed. Therefore, the present study aims to evalu-
ate the accuracy of CTP to visualize the coagulation necrosis after MWA, proposing thresholds as partial guidance 
for an improved delineation of the necrotic area.
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Results
Overall, 10 ablations were evaluated. Histologically, the mean necrotic area size was 204.8 mm² with a mean 
maximum diameter of 18.1 mm. The best correlations with histology could be shown for measurements taken in 
perfusion maps of HBV and AF, which sowed correlation coefficients of r = 0.73 and r = 0.72, both being superior 
to CECT measurements, respectively. The mean size of the coagulation necrosis was 199.2 mm² for HBV with a 
mean maximum diameter of 17.5 mm, which represented an underestimation of the true coagulation necrosis 
extend, as defined by histology. For AF, the mean size was 308.7 mm² with a mean diameter of 22.3 mm, which 
corresponded to overestimation of the true size. However, compared to the histologic reference standard, these 
differences were not statistically significant (p = 0.535 for AF and p = 0.083 for HBV). The mean squared error, 
as a measurement of deviations between CT measurements and histology, with higher values corresponding to a 
poorer fit to the reference standard, was lowest for HBV and second lowest for AF (97 for HBV and 148 for AF). 
The measurements from CECT-images showed an overall good correlation with histology (r = 0.59), but also an 
overestimation of the ablations true size with a measured mean coagulation necrosis of 334.4 mm², correspond-
ing to a significant overestimation (p = 0.038). The mean squared error of size measurements in CECT was 169.
Other perfusion maps showed a lower suitability for visualizing the extent of the coagulation necrosis with an 
inferior performance compared to the CECT. Although a higher correlation with the histologic reference stand-
ard could be observed for PF, TF and MTT with r = 0.7, r = 0.68 and r = 0.65, respectively, all of these parameters 
showed a significant overestimation of the coagulation necrosis extend (p < 0.05) and larger mean squared errors 
than CECT. A detailed overview of measured ablation sizes is provided by Table 1.
Table 1 provides the mean size in mm² of the coagulation necrosis as measured in the histologic reference 
standard, contrast enhanced CT and the various CT perfusion maps. It shows that hepatic blood volume is the 
most accurate to display coagulation necrosis compared to histology. The p-value for the t-test for comparison 
of the size of coagulation necrosis between the histologic reference standard and parameter maps is given in the 
second row, showing a significant overestimation for contrast enhanced CT, portal venous flow and mean transit 
time. Correlation of the measured size with the reference standard is given in the third row and the mean squared 
error between size measurements in histology and contrast enhanced CT or CT perfusion can be obtained from 
the last row.
Diagnostic accuracy. Accuracies for CECT and the different perfusion maps, subdivided by individual 
ablated areas, are provided by Table 2. Overall, perfusion maps of AF and HBV, both showing a decrease of values 
in the dead tissue, were significantly superior for the visualization of coagulation necrosis compared to CECT 
(p < 0.001). A summary ROC-curve for AF, HBV and CECT is provided by Fig. 1.
The true positive rate/false discovery rate of HBV was 89%/25%, using an upper threshold of 29 ml. The true 
positive rate indicates, that 89% of the necrotic zone was displayed correctly by HBV and the false discovery 
rate indicates that 25% of the area displayed by the HBV as necrotic, did not correspond to necrotic tissue in the 
histologic reference standard, i.e. was displayed incorrectly by HBV. The overall agreement/disagreement ratio 
off HBV was 2.81. An agreement/disagreement ratio of 1 would indicate that the sum of the true positive pixels 
is equal to the sum of the false positive and false negative pixels. Accordingly, if the ratio is less than 1, the sum of 
false positive and false negative pixels is larger than the sum of true positive pixel, and if the ratio is greater than 
1, the sum of true positive pixels is larger.
For AF, when an upper threshold of 74 ml/min was used, necrotic areas in the ablated zone were identified 
with a true positive rate/false discovery rate ratio of 90%/50% and an agreement/disagreement ratio of 0.82. 
CECT had lower accuracy than both HBV and AF, but higher accuracy than the other perfusion maps (PF, TF 
and MTT). Using an upper threshold of 200 HU, an agreement/disagreement ratio of 0.66 could be achieved with 
a true positive ratio of 81% and a false discovery rate of 52%.
For portal venous blood flow and total hepatic blood flow, which also showed decreased flow rates in the cen-
tre of the ablations, an even higher agreement in the visualization of necrotic zones could be reached with true 
positive rates of 97% and 100% respectively, however, this was achieved at the expense of a higher false discovery 
rate of 63% and 60% and consequently lower agreement/disagreement ratios of 60% and 73% respectively. Mean 
transit time (MTT) was decreased in the centre of ablation. For an upper threshold of 38 s, a true positive rate/










Contrast enhanced CT 334.4 21.0 0.038 0.59 169
CT Perfusion
  Hepatic blood volume 199.2 17.5 0.535 0.73 97
  Hepatic arterial blood flow 308.0 22.3 0.083 0.72 148
  Portal blood flow 359.8 24.0 0.012 0.70 178
  Total blood flow 365.5 23.7 0.017 0.68 181
  Mean transit time 356.3 23.7 0.009 0.65 172
Table 1. Size comparison of contrast enhanced CT and CT-perfusion against the histologic reference standard.
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Table 2 provides the individual measurements of accuracy for contrast enhanced CT and the various CT per-
fusion maps. It shows that arterial blood flow and hepatic blood volume both allow for a more accurate depiction 
of the coagulation necrosis than CECT. For each modality the true positive rate (TPR, higher equals better), false 
detection rate (FDR, lower equals better) and agreement-disagreement ratio (ADR, higher equals better) are 
listed. The pooled accuracies are given under the respective individual values. Finally, in the last row, the cut-off 
used to calculate the accuracies for all ablations are given. HU = Hounsfield units.
Discussion
The results of the present study show that CTP-parameter maps of arterial blood flow and hepatic blood volume 
allow for an improved visualization of the coagulation necrosis immediately after ablation in a porcine model of 
MWA. In clinical practice, this could enable earlier detection of incomplete ablations and thus a timely re-ablation 
in the same session, potentially reducing the number of local recurrences. The current study also shows that the 
results of CT perfusion were objectifiable across the animals, as it was possible to establish common thresh-
olds for perfusion values. This suggests that similar thresholds could also be established for humans, and thus 
improve accuracy of post-procedural imaging. Still, the relatively small sample should also be considered when 

























Ablation 1 99 54 0.83 100 57 0.76 100 59 0.71 100 53 0.89 100 29 2.42 100 59 0.7
Ablation 2 99 63 0.59 100 59 0.7 100 65 0.54 100 48 1.1 91 5 6.58 99 68 0.47
Ablation 3 59 47 0.63 76 33 1.23 100 48 1.07 100 39 1.57 96 11 5.9 100 49 1.06
Ablation 4 72 69 0.38 7 53 0.65 95 68 0.45 100 69 0.45 80 47 0.87 100 69 0.45
Ablation 5 17 13 0.19 59 06 1.34 100 80 0.25 100 80 0.25 99 28 2.54 100 80 0.25
Ablation 6 95 43 1.27 100 58 0.73 099 58 0.72 100 58 0.73 99 43 1.32 98 49 1.02
Ablation 7 100 58 0.73 100 58 0.73 100 58 0.73 100 58 0.73 95 17 3.97 100 55 0.83
Ablation 8 89 73 0.36 100 69 0.46 100 71 0.41 100 71 0.41 92 37 1.47 100 68 0.48
Ablation 9 79 45 0.92 94 54 0.8 80 67 0.44 100 70 0.42 70 17 1.57 100 67 0.48
Ablation 10 97 57 0.74 100 57 0.75 100 58 0.73 100 58 0.73 66 16 1.42 95 57 0.73
Pooled 81 52 0.66 90 50 0.82 97 63 0.6 100 6 0.73 89 25 2.81 99 62 0.65
Cut-off 200 HU 74 ml/min 75 ml/min 100 ml/min 29 ml 38 sec
Table 2. Individual measurements of accuracy for contrast enhanced CT and CT-perfusion.
Figure 1. Shows summary receiver operator characteristic (SROC) curves for the accuracy of hepatic blood 
volume (HBV), hepatic arterial blood flow (AF) and contrast enhanced computed tomography (CECT). On the 
left, the SROC curves of all three parameter maps with the summary estimate for the overall accuracy and its 
95% confidence interval is provided. The three subplots on the right represent the individual SROC curves, and 
the points represent pairs of true positive and false discovery rates in individual ablations. HBV provides the 
highest accuracy with an area under the SROC-curve (AUC) of 0.85, followed by AF and CECT. Also, the 95% 
CI of the summary estimate for HBV does not overlap with the 95% CI for AF or CECT. Between the 95% CI of 
AF and CECT some overlap can be seen, which could indicate that AF might not perform better than CECT in 
a different sample.
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interpreting these results, especially for AF. As can be seen in Fig. 1, the confidence intervals for the summary 
estimate overlapped between AF and CECT, which may be an indication that, given a different sample size, the 
AF might no longer perform better than CECT. It should also be considered that CECT and AF showed overesti-
mation of the coagulation necrosis’ size, which may result in erroneously assessing the ablation size as sufficient, 
while tumour still persists in the transitional zone.
The CT-based visualization of the central necrotic zone following thermoablation was not explicitly stud-
ied previously, as the primary focus of earlier studies was on the identification of ablation margins, overall size 
assessment or cross-modality comparison of CT to ultrasound, elastography or positron emission tomography 
(PET)3,10,14–19. However, since vital tissue still exists in outer ablation zones and the boundaries of the necrotic 
areas cannot be reliably extrapolated from the outer shape of the ablation6,7,20, the delineation of the outer ablation 
margins alone is no accurate measure of the success of ablation9. Although, as in surgery, a safety zone of 5 mm is 
recommended for MWA, local recurrence rates are reported to be comparatively higher after ablation21–23. Ringe 
et al. showed that the technical success of MWA correlated poorly with the local recurrence rate24. So far, mag-
netic resonance imaging (MRI) appears to be the most accurate modality for assessing the outcome of MWA24–26. 
However, immediate control of ablation using MRI would require either the transfer of the patient from the inter-
vention site to the MRI facility, precluding immediate on-site re-ablation if residual tumor tissue is detected in 
the target area, or the on-site performance of MRI-guided MWA. For the latter, however, MRI-suitable materials 
are needed, and so far, most available devices are not MRI safe. However, if MRI-suitable materials can be used 
novel studies showed that MRI can accurately display the ablation zones and could also be used as real-time mon-
itoring27,28. Still, accuracy of needle placement can be hampered in some MRI systems by the comparably narrow 
gantry, unless an open MRI system is used29,30. For these reasons, CTP could shorten and simplify post-ablational 
imaging procedures, as there is no need to switch from CT to MRI and early re-ablation can be performed on site 
easily, time- and cost-efficiently. However, this time gain in post-ablational imaging comes at the expense of addi-
tional radiation exposure and contrast agent administration, especially if the first ablation proves to be insufficient 
and re-ablation with subsequent re-imaging is required.
Our study has limitations: Due to the methodology of comparing images of ablations with histological sec-
tions, a small disagreement, due to the fixation process of the tissue, can never be avoided possibly degrading 
the results we obtained for the performance of CECT/CTP. Also, ablations were performed in healthy pigs. The 
pig liver differs from the human liver in that it contains more interlobular connective tissue, which could affect 
heat distribution and thus the appearance of the coagulation necrosis31. Furthermore, we performed ablations 
in tumor-free livers. Hence, the findings of this work cannot be fully translated to the ablation and perfusion 
behaviour of (ablated) tumor tissue, as heat dispersion and development of necrosis may differ in tumor tissue. 
In addition, it was not possible to evaluate whether tumor tissue would have remained in the transitional zone 
after an ablation, even though the extent of the ablations seemed sufficient after perfusion imaging in healthy liver 
tissue. A further limitation is, that a single cut-off was selected for each perfusion map and the CECT-images to 
calculate the accuracies, as this is the only way to generalize the results. However, the generalized cut-off differs 
from the ideal cut-off for each individual ablation. Finally, the use of shuttle perfusion may also contribute to a 
decrease in CTP accuracy, since continuous bi-directional table movement causes temporal shifts in the recording 
of the same contrast medium phase at the upper and lower edge of the examined region. Short contrast-phases, 
such as maximum arterial enhancement, could be blurred, and the motion and time corrections performed dur-
ing pre-processing are likely limited. During data analysis, we also observed that it was difficult to establish a 
cut-off for ablations directly adjacent to the diaphragm, because the algorithm used for image segmentation did 
not recognize ablation boundaries when perfusion and/or attenuation values in the adjacent diaphragm or lungs 
were too low. However, this should not cause any problems for a human observer, as these structures are easy to 
recognize in CT images and/or overlaid perfusion maps. Nevertheless, it is still advisable to maintain a sufficiently 
large safety margin during ablation. Finally, it has been shown, that the inner portions of the transitional zone 
deteriorate in the first 12 hours after ablation, indicating a further expansion of the coagulation necrosis32. due 
to the immediate explantation of the pig livers, in our experiment, histology might have underestimated the true 
extent of final coagulation necrosis.
Overall, the here presented approach for visualizing post interventional coagulation necrosis using CTP 
allowed for an improved delineation of the necrotic area compared to standard CECT.
In conclusion, CT-perfusion is superior to CECT in the delineation of the necrotic tissue after hepatic micro-
wave ablation, particularly when assessment is based in the visualization of the reduced hepatic blood volume and 
arterial perfusion of ablations.
Materials and Methods
Animals, housing and care. This prospective animal study was approved beforehand by the National Office 
for Health and Social Affairs as well as by the institutional review board of Charité Universitätsmedizin Berlin and 
conducted according to the guidelines and rules of the Federation of Laboratory Animal Science Associations. 
The animals were kept under controlled conditions in our department’s animal facilities complying with the 
specifications of local guidelines and the Animal Welfare Act. Microwave ablations and CTP were performed in 
five domestic pigs. The pigs were anesthetized throughout the procedure and were cared for by an experienced 
veterinarian.
Microwave ablation. All ablations were performed under CT guidance using an 80-Slice CT-scanner 
(Aquilion Prime, Canon Medical Systems Corporation, Japan). Before placement of the antennas (AveCure, 
MedWaves Incorporated, San Diego, USA), the liver was exposed by median laparotomy to ensure more pre-
cise needle positioning. Each ablation was performed with a power of 100 W, delivering a target energy of 24 kJ 
into the tissue and followed by CTP. Before needle retraction, a 2-cm plastic tube was inserted centrally into the 
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ablation, enabling reliable re-location of the ablation axis and histological sectioning orthogonally to the axis in 
the ablation center. Between one and two ablations with subsequent CTP were performed per animal.
Histological sections. The preparation of histological slices was performed by an experienced veterinarian 
who was supervised by a veterinary pathologist. After liver explantation, ablations were resected in toto and cut 
orthogonally through the axis, as indicated by the plastic tube. A specifically designed template was used for accu-
rate cutting33. Ablations were embedded in Tissue-Tek-O.C.T.-Compound (Sakura-Finetek-Germany GmbH, 
Germany) and deep-frozen. Histological sections were obtained with a cryostat (CryoStar-NX70-Cryostat, 
Thermo-Fischer-Scientific, USA) and mounted on glass slides. Thereafter, sections were stained according to 
a protocol of Neumann et al. using a Hematoxylin & Eosin and a nicotinamide adenine dinucleotide (NADH) 
and nitro blue tetrazolium chloride (NBTC) solution34. Subsequently, sections were photographed with a digital 
microscope (BZ-X810, Keyence-Cooperation, Japan) and stitched using the ImageJ-2D/3D-Stitching-Plugin35,36. 
The zone of coagulation necrosis was semi-automatically segmented with the fuzzy-selection tool of the 
GNU-Image-Manipulation-Program (The-GIMP-Team, GIMP2.8.10, www.gimp.org, 1997–2018) and exported 
in the standard Digital Imaging and Communications in Medicine (DICOM) format.
ct-perfusion. The same scanner was used for MW-needle positioning and CTP. Scan parameters were: 
100 kV, 200 mA, 0.35 s rotation time and 1 mm reconstructed slice thickness. For full liver coverage, CTP was 
performed in shuttle mode with constant bidirectional table movement covering an area of 16 cm, with the acqui-
sition of 40 CT volumes over the course of 3 seconds for each volume. During CTP, 40 ml iomeprol (Imeron 400, 
Bracco Imaging, Italy) were injected at 5 ml/s. Thereafter, images were co-registered with a non-rigid algorithm to 
reduce motion artifacts and, because of shuttle perfusion, time correction was applied. Images were reconstructed 
using a FC11 convolution kernel.
contrast enhanced ct. Contrast enhanced CT was performed after CTP and after injection of 100 ml iome-
prol (Imeron 400, Bracco Imaging, Italy) at a speed of 4 ml/s. Scan parameters for CECT were 120 kV, 400 mA, 
0,5 s rotation time and 0,5 mm slice thickness with FC 11 convolution kernel.
The “Research PC”, software version V6.0SP0500EWiP, (Canon Medical Systems Corporation, Japan) was 
used for further data readout. For all evaluations, a hepatic dual input deconvolution algorithm with a box-like 
impulse residue function was applied, allowing calculation of hepatic blood volume (HBV), hepatic arterial blood 
flow (AF), portal venous blood flow (PF), total hepatic blood flow (TF) and mean transit time (MTT). Finally, 
multiplanar reconstructions of CECT and CTP-scans (corresponding to the histological sections) were exported 
in DICOM format.
Figure 2. Schematically shows the image analysis procedure. First the images (in this case CECT) were 
imported (1A), then grey level mapping was applied, showing only values between 0 and a given cut-off value, 
transforming the image into a binary image (1B). The ablation was then isolated by a region-growing algorithm 
(1C).
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Data analysis. Data and statistical analysis was performed using the “R” statistical software (Version 3.5.0, 
2018) including the “ggplot2” package for graphic display and “oro.dicom” for reading DICOM images37–39. 
Images were scaled to a unified pixel size and imported as two-dimensional arrays. Rescaling of attenuation 
values was performed using the rescale-slope and intercept stored in the DICOM header. Subsequently, ablations 
were isolated by first setting an upper threshold for the attenuation or perfusion, then strictly windowing the 
images according to the predefined threshold to obtain binary image and finally applying a region growing algo-
rithm (see Fig. 2). The isolated ablation was overlaid by the histologic segmentation to count matching pixels (true 
positives) and non-matching pixels (false positives and false negatives). The overlay procedure and calculation of 
true positives, false positives and false negatives are illustrated by Fig. 3. To reduce overlay errors, the previously 
inserted plastic marker was used to avoid shifting between the images33. To adjust rotation of the images to each 
other, adjacent vessels and, in some sections, the nearby liver surface were used. For each CECT and CTP image, 
this procedure was repeated with thresholds varying between 1 and the maximum of the pixel values in the cor-
responding image.
In the histological images (liver sections stained with NADH-vital stain), the central part of coagulation necro-
sis and the transitional zone containing residual vital tissue (also referred to as red-zone) were semi-automatically 
segmented (1D) and isolated (1E). Finally, the segmented coagulation necrosis was overlaid with the CECT or 
CTP image to calculate the accuracy. HU = Hounsfield units.
Statistical analysis. Based on counts of true positives, false positives and false negatives, the true positive 
rate (which equals the agreement between histologic reference standard and CECT/CTP), false discovery rate 
(disagreement between CECT/CTP and histologic reference) and agreement-disagreement-ratio (pixel-sum of 
true positives divided by pixel-sum of false positives and false negatives) were calculated. Using repeated meas-
urements with varying thresholds, we performed a receiver operator characteristic (ROC) analysis to identify 
the threshold for optimal display of the coagulation necrosis in the corresponding image and across all measure-
ments. Accuracies were compared using the chi-squared test. The overall accuracy was also displayed in sum-
mary ROC curves (Fig. 1). Extents of coagulation necrosis were calculated over the absolute pixel number. Size 
measurements were compared to the histologic reference standard using student’s t-test, Pearson’s correlation 
coefficient and the mean squared error. A p-value < 0.05 was considered statistically significant.
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author 
upon reasonable request.
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Figure 3. Shows a comparison in display of the coagulation necrosis of histology (Hematoxylin and eosin stain) 
(2A), contrast enhanced CT (2B) and perfusion maps of hepatic arterial flow (2C) and hepatic blood volume 
(2D). Under the respective original images, the segmented coagulation necrosis of the gold standard is shown 
in light red (2E) and the display of the coagulation necrosis by the corresponding modality in dark grey (2F for 
Contrast enhanced CT, 2G for hepatic arterial flow, 2H for hepatic blood volume). For each modality, the cut-off 
described in Table 2 was used.
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